Our History and Heritage A century of combined legacy
Curium’s journey began in the 1980’s and when two nuclear medicine powerhouses, IBA Molecular and Mallinckrodt Nuclear Medicine LLC, came together, our vertically integrated company with a single focus on nuclear medicine was created.
From scientific origins to global scale
Our legacy companies developed a variety of radioisotopes that helped grow Curium from a handful of individual founders into a global nuclear medicine company of over 3,800 people.
The Curium Group
Curium is an independent global company with operations across North America, Europe, and Asia-Pacific, dedicated exclusively to nuclear medicine and focused on delivering innovative radiodiagnostic and radiotherapeutic solutions to patient’s worldwide.
$7bn Recapitalisation
In 2026, together with CapVest, Curium announced its recapitalization via a new Continuation Vehicle, valuing Curium at $7 billion. This marked the largest global transaction in nuclear medicine and accelerates our strategy to expand access to our established radiodiagnostic products and launch innovative radiotherapeutics globally.
Marie Curie’s Legacy
Marie Curie’s discoveries in radioactivity laid the foundations of nuclear science and medicine. Curium is a chemical element named in honor of Marie and Pierre Curie, reflecting this enduring scientific legacy
IBA Founded Publicly
The medical innovator, Yves Jongen, created “Ion Beam Applications” known as IBA SA which was listed on the Belgian Stock Exchange 2 years later
IBA SA listed on Belgian Stock Exchange
IBA SA (IBAB) is a Belgian company listed on Euronext Brussels and a global leader in proton therapy technology
CIS Bio Acquisition
IBA acquired CIS Bio, which was Schering AG’s radiopharmaceutical business
SK Capital Carveout
IBA Molecular was carved out from IBA by SK Capital, as a nuclear medicine focused company
European Expansion
IBA Molecular began to expand across Europe, starting in Spain by acquiring Molypharma closely followed by Instituto Tecnológico PET a few years later
CapVest acquires IBA Molecular
CapVest acquired IBA Molecular to create a global nuclear medicine leader, while Instituto Tecnológico PET (Spain) joined the group
Creation of Curium
IBA Molecular acquired Mallinckrodt Nuclear Medicine, combining two major nuclear medicine businesses and Curium was created
Cyclopharma Acquisition
Acquired Cyclopharma and its 5 PET sites in France
European PET Expansion
- In-licensed 18F-DCFPyL in Europe from Progenics
- Acquired MAP Medical Technologies in Finland
- Acquired ACOM’s operations in Italy, expanding Curium’s European PET footprint
US Manufacturing Expansion
Acquired Zevacor’s Noblesville facility in Indianapolis, US, which included the first commercial 70 MeV
Further European PET Expansion
Acquired Molecular Imaging Institute (M2i) Ltd (Ireland) and IASON (Austria), adding three PET sites, and in-licensed Exini’s PSMA AI software for Europe
Curasight
In-licensed Curasight’s 64Cu-based PET imaging technology
International Expansion into Growth Markets
- Acquired Nucleis, a manufacturer and distributor of F18 tracers in the Benelux region It is now Curium PET Liège
- Acquired Eczacıbaşı Monrol, now Curium Türkiye, – Türkiye’s largest radiopharmaceutical distribution network
- Curium announced headquarters move to Boston, MA United States
PET Radiodiagnostic Pipeline Expansion
- Curium announced definitive agreement to merge with Lantheus entering in the U.S. market for diagnostic solutions targeting Neurology and Echocardiography
- Curium acquired Abscint SA, a Belgian clinical-stage radiopharmaceutical company, with a focus in breast and gastric cancers
